Dear editors,

Thank you very much for your invitation of submission of our revised manuscript " CD56+ lymphoepithelioma-like carcinoma of the lung: An unusual case and literature review (manuscript NO: 53210)".

We have thoroughly addressed the concerns from the reviewer in this revised manuscript. All the changes were tracked in this revised manuscript. We responded to the comments from the reviewer point-by-point. For clarity, we present the critiques first followed by our responses in italics.
In addition, we updated our manuscript according to the Guidelines and Requirements for Manuscript Revision (**line 11, 13, 21, 28-31, 41, 84-85**: authors' name format correction; **line 19**: Province information; **line 39**: supporting information; **line 41**: corresponding author's title; **line 47-54**: Open access information; **line 88-89**: Copyright information).

We believe that this fairly improved manuscript is now acceptable for publication. Your consideration of our manuscript will be greatly appreciated.

Sincerely,
Xingsheng Hu
Department of Medical Oncology
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, 100021
China
Phone: +86-13641361385
Email : huxingsheng66@163.com

Response to Reviewer's Comments:

1. Page 6, Laboratory examinations: please provide reference ranges for the tumor markers.
A: Thanks for the critical comments. We have added the reference ranges for the tumor markers as follows (line 146-147):

The investigation of serum tumor markers showed that the cancer antigen 125 (CA125), cytokeratin fragment antigen 21 (Cyfra21), and neuron-specific enolase (NSE) were 37.7 U/mL, 13.68 ng/mL, and 76.71 ng/mL, ***with the corresponding upper limit of normal of 35 U/ml, 3.3 ng/mL and 16.3 ng/mL****, respectively.*

2. Page 18, Figure 1C. Did you mean nuclear medicine imaging instead of magnetic resonance imaging?
A: Thanks for the careful reviewing. We have corrected this mistake (line 496).